Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8751500 | 0.80 | TSHR (0.38) | — | |
| SCHEMBL28276519 | 0.77 | TRPM8 (0.37) | — | |
| SCHEMBL27336443 | 0.71 | TSHR (0.57) | ACHEPOLB | |
| SCHEMBL80155 | 0.71 | CTSA (0.56) | CTSAACHEKDM4EALDH1A1POLB | |
| SCHEMBL3819715 | 0.69 | TSHR (0.60) | CTSAACHEKDM4EALDH1A1POLB | |
| SCHEMBL86164 | 0.69 | TSHR (0.60) | CTSAACHEKDM4EALDH1A1POLB | |
| Fluoride SCHEMBL27939414 | 0.68 | CTSA (0.53) | CTSAACHEKDM4EALDH1A1POLB | |
| SCHEMBL23979197 | 0.68 | KDM4E (0.42) | CTSAACHEKDM4EALDH1A1POLB | |
| SCHEMBL4758289 | 0.67 | CTSA (0.46) | CTSAACHEKDM4EALDH1A1POLB | |
| SCHEMBL11661505 | 0.67 | TSHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | claimed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | claimed |
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | claimed |
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | disclosed |
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434210-B2 | Method for synthesizing valsartan | REN, ACE, AGT | CTSA 1110/4885ACHE 2397/4885KDM4E 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.